Emideltide narrowly voted down by FDA peptide advisory panel on Day 2 on July 24, 2026 Advisory Committees compounding pharmacies Delta Sleep-Inducing Peptide Emideltide Opioids PCAC Peptides sleep-inducing peptide Sleeplessness United States Food and Drug Administration Withdraw (activity) +
FDA Proposes to Withdraw Approval of Amgen's Tavneos Over Data Manipulation and Safety Issues on April 28, 2026 Amgen ANCA vasculitis Approved data manipulation Injury of liver Tavneos United States Food and Drug Administration Withdraw (activity) +
Ipsen Withdraws Cancer Drug Tazverik from Market Due to Secondary Blood Cancer Risks on March 09, 2026 Antineoplastic Agents Ipsen Risk Safety secondary blood cancers SYMPHONY-1 trial tazemetostat Tazverik Withdraw (activity) +
PTC Therapeutics Withdraws US NDA for Translarna in Nonsense Mutation Duchenne Muscular Dystrophy on February 13, 2026 ataluren factor IX Muscular Dystrophy, Duchenne NDA Translarna United States Food and Drug Administration Withdraw (activity) +
Mikael Dolsten Withdraws Candidacy for Novo Nordisk Board; Bavarian Nordic Chairman Resigns on November 14, 2025 Bavarian Nordic Board of Directors board shake-up chairman resignation Danish pharma Mikael Dolsten Nordisk personal reasons Withdraw (activity) +
Lack of Transparency Tarnishes Sarepta's Sheen as Patient Deaths Trigger FDA Battle on July 23, 2025 Elevidys gene therapy lack of transparency Market Muscular Dystrophies, Limb-Girdle Muscular Dystrophy, Duchenne patient deaths Regulatory Action United States Food and Drug Administration Withdraw (activity) +
FDA Threatens Action After Sarepta Refuses to Halt Elevidys Shipments on July 21, 2025 Elevidys gene therapy Liver Failure Market Muscular Dystrophy, Duchenne patient deaths Regulatory Authority United States Food and Drug Administration Withdraw (activity) +
Sarepta Stands Behind Elevidys After FDA Requests Withdrawal Amid Safety Concerns on July 21, 2025 Cessation of life Clinical Trials concerns Elevidys gene therapy Market Muscular Dystrophy, Duchenne Safety United States Food and Drug Administration Withdraw (activity) +
Odyssey Therapeutics Abandons IPO Plans in Latest Sign of Tough Environment for Biotech Listings on June 10, 2025 Autoimmune IPO Market Odyssey seconds turbulence Withdraw (activity) +